Diabetes

Top news of the day from across the health care landscape.

Health care delivery must change to meet the increasing demands for conservative stewardship in spending.

Long-term effects found among patients with diabetes who survive heart attacks.

About 11 million patients 65 years or older were diagnosed with diabetes in 2012 alone.

Approximately 58% of patients with nonalcoholic steatohepatitis treated with pioglitazone showed reduced disease activity.

Gestational diabetes significantly increases the risk of developing type 2 diabetes within 5-years after giving birth.

It's no secret that our canine companions possess a remarkable sense of smell, but did you know they've used it to save lives by alerting patients to health problems before they even occur?

Elevated levels of RBFOX2 found in diabetic heart tissue could cause heart damage.

Skin cells from diabetic foot ulcers could be reprogrammed to acquire properties of embryonic-like cells.

Children and adolescents with JIA are also likely to develop other autoimmune diseases beyond diabetes.

Volanesorsen improved insulin sensitivity and glucose control in type 2 diabetes.

Mindfulness-based treatments may benefit patients with type 2 diabetes.

The No. 1 cause of death, cardiovascular disease, is preventable.

At some point in your career, you've probably encountered questions from patients or health care team members about diabetes medications' stability and how the products are supplied.

More work is need to determine the impact of weight loss programs in lowering blood sugar concentrations in type 2 diabetes.

Protease inhibitors can frequently lead to cardiovascular disease, diabetes, and obesity.

Researchers assess the monetary value for improved health status.

Darapladib can block Lp-PLA2, which can lead to diabetes-related vision loss.

Researchers evaluate the link between organ transplant and the increased likelihood of developing diabetes.

Approximately 24 to 25% of patients with type 2 diabetes and heart failure died within 18 months.

New data from the EMPA-REG OUTCOME trial showed the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) significantly reduced the incidence of worsening kidney disease in type 2 diabetes patients.

Merck and Pfizer teamed up to create a new type 2 diabetes drug.

Anti-fetal brain autoantibodies shown to be specific to some mothers of children with autism.

Metformin has been found to reduce the need for insulin in diabetics.

Diabetic macular oedema could be reduced by the cardiovascular drug darapladib.